SOPHiA GENETICS and AstraZeneca have partnered to accelerate the deployment of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDMTM to 20 locations worldwide over the next 12 months. This partnership aims to expand access to liquid biopsy testing, particularly in underserved populations, and generate real-world data to advance cancer research.